Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Wilkins

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Current Opinion in Lipidology|September 9, 2022
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future researchJohn T Wilkins, Anand Rohatgi
JAMA|March 5, 2023
The Urgent Need to Refocus Cardiovascular Disease Prevention Efforts on Young AdultsNorrina Allen, John T Wilkins
Current Opinion in Lipidology|December 12, 2018
HDL modification: recent developments and their relevance to atherosclerotic cardiovascular diseaseJohn T Wilkins, Henrique S Seckler
Circulation. Population Health and Outcomes|February 24, 2026
Optimizing Blood Pressure Targets in Patients With Cardiovascular Disease: Rethinking Control in Terms of Time in RangeNorrina B Allen, John T Wilkins
Current Opinion in Endocrinology, Diabetes, and Obesity|January 12, 2018
Discordance between lipoprotein particle number and cholesterol content: an updateEric P Cantey, John T Wilkins
JAMA|July 20, 2021
Novel Lipid-Lowering Therapies to Reduce Cardiovascular RiskJohn T Wilkins, Donald M Lloyd-Jones
Nature Reviews. Cardiology|May 17, 2016
Prevention: HOPE-3 trial - targeting BP and LDL-C in at-risk patientsJohn T Wilkins, Donald M Lloyd-Jones
Circulation|June 15, 2026
Clinical Guidelines, Market Forces, and Health DisparitiesCiaran N Kohli-Lynch, John T Wilkins
Preventive Cardiology|September 24, 2010
Biomarkers for coronary heart disease clinical risk prediction: a critical appraisal. CounterpointJohn T Wilkins, Donald M Lloyd-Jones
JAMA Cardiology|October 26, 2022
Icosapent Ethyl Supplementation and Cardiovascular Prevention-Implications of Evolving DataJohn T Wilkins, Donald M Lloyd-Jones
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Current Opinion in Lipidology|September 9, 2022
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future researchJohn T Wilkins, Anand Rohatgi
JAMA|March 5, 2023
The Urgent Need to Refocus Cardiovascular Disease Prevention Efforts on Young AdultsNorrina Allen, John T Wilkins
Current Opinion in Lipidology|December 12, 2018
HDL modification: recent developments and their relevance to atherosclerotic cardiovascular diseaseJohn T Wilkins, Henrique S Seckler
Circulation. Population Health and Outcomes|February 24, 2026
Optimizing Blood Pressure Targets in Patients With Cardiovascular Disease: Rethinking Control in Terms of Time in RangeNorrina B Allen, John T Wilkins
Current Opinion in Endocrinology, Diabetes, and Obesity|January 12, 2018
Discordance between lipoprotein particle number and cholesterol content: an updateEric P Cantey, John T Wilkins
JAMA|July 20, 2021
Novel Lipid-Lowering Therapies to Reduce Cardiovascular RiskJohn T Wilkins, Donald M Lloyd-Jones
Nature Reviews. Cardiology|May 17, 2016
Prevention: HOPE-3 trial - targeting BP and LDL-C in at-risk patientsJohn T Wilkins, Donald M Lloyd-Jones
Circulation|June 15, 2026
Clinical Guidelines, Market Forces, and Health DisparitiesCiaran N Kohli-Lynch, John T Wilkins
Preventive Cardiology|September 24, 2010
Biomarkers for coronary heart disease clinical risk prediction: a critical appraisal. CounterpointJohn T Wilkins, Donald M Lloyd-Jones
JAMA Cardiology|October 26, 2022
Icosapent Ethyl Supplementation and Cardiovascular Prevention-Implications of Evolving DataJohn T Wilkins, Donald M Lloyd-Jones
Pageof 14